Suggested remit: To appraise the clinical and cost effectiveness of atezolizumab with cobimetinib and vemurafenib within its marketing authorisation for treating unresectable or metastatic BRAF V600 mutation-positive melanoma.
Status In progress
Process STA 2018
ID number 1674

Project Team

Project lead Michelle Adhemar

Email enquiries


Key events during the development of the guidance:

Date Update
02 October 2019 - 30 October 2019 Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators
31 July 2017 In progress, DHSC Referral Received

For further information on how we develop guidance, please see our page about NICE technology appraisal guidance